Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
50 results about "Glycogen phosphorylase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Glycogen phosphorylase is one of the phosphorylase enzymes (EC 2.4.1.1). Glycogen phosphorylase catalyzes the rate-limiting step in glycogenolysis in animals by releasing glucose-1-phosphate from the terminal alpha-1,4-glycosidic bond. Glycogen phosphorylase is also studied as a model protein regulated by both reversible phosphorylation and allosteric effects.
Pharmaceutical compositions of a sparingly soluble glycogen phosphorylase inhibitor
InactiveUS7235260B2Improve aqueous concentrationIncrease concentrationBiocidePowder deliveryGlycogen phosphorylaseDosage form
Pharmaceutical compositions of a particularly effective sparingly soluble glycogen phosphorylase inhibitor are disclosed, as well as methods of making such compositions and dosage forms from such compositions.
Owner:BEND RES
Use of pentacyclic triterpene compound as glycogen phosphorylase inhibitor
An application of the pentacyclo-triterpenoid used as the glycogen phosphorylase for preparing the medicines to treat diabetes, ischemic cardiovascular and cerebrovascular diseases, and tumor is disclosed.
Owner:CHINA PHARM UNIV
Liver-targeted glycogen phosphorylase inhibitor cholic acid derivative and preparation method and medical application thereof
The invention relates to a glycogen phosphorylase inhibitor cholic acid derivative, a preparation method thereof and a pharmaceutical composition containing the same. The glycogen phosphorylase inhibitor cholic acid derivative is a liver-targeted pro-drug for glycogen phosphorylase; compared with a glycogen phosphorylase inhibitor, the concentration of the glycogen phosphorylase inhibitor in a liver can be increased after the glycogen phosphorylase inhibitor cholic acid derivative is taken orally, so that the glycogen phosphorylase inhibitor cholic acid derivative can serve as a preferred drug for lowering blood sugar, particularly for treating impaired fasting glucose. The compound can be used for preventing and treating diabetes and complications thereof, hyperlipidemia, obesity, high-glucagon disease, insulin resistance, impaired fasting glucose, hypertension and complications thereof, atherosclerosis, metabolic syndrome or tumor.
Owner:CHENGDE MEDICAL UNIV
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
Prodrugs of glycogen phosphorylase inhibiting compounds are provided which are useful in treating diabetes, having the formula IG(—O2CR′)m(—OH)n(—O2C(CH2)pCH3)qIwherein G is a C3 to C5 branched or straight carbon chain and (—O2CR′), (—OH) and (—O2C(CH2)pCH3) are attached to any available carbon atom along G;—O2CR′ is a fragment of a compound of formula Ibwhere W is a bicyclic heteroaryl; m, n, p, q, X, Y, Z, R1 and R2 are as defined herein, as exemplified byFurther provided are pharmaceutical compositions and methods for treating diabetes and related diseases employing the above compounds above, either alone or in combination with another therapeutic agent.
Owner:BRISTOL MYERS SQUIBB CO
Method for enzymatically synthesizing astragalin
InactiveCN105463044AFew stepsMild operating conditionsFermentationEnzymatic synthesisDihydro-kaempferol
The invention provides a method for enzymatically synthesizing astragalin. The method comprises the following steps that 1, key enzymes needed in the synthesizing process of astragalin are cloned, expressed and purified, wherein the key enzymes comprise glycogen phosphorylase GP, glucose pyrophosphorylase GalU, flavanone-3-hydroxylase F3H, flavanone synthase FLS1 and flavonoid3-O-glucanotransferase UGT78K2; 2, glycogen Gn is synthesized into glucose-1-phosphoric acid G-1-P under the GP effect; 3, G-1-P is synthesized into uridine diphosphate UDPG under the GalU effect; 4, naringenin NRN is synthesized into dihydro kaempferol DHK under the F3H effect; 5, DHK is synthesized into kaempferol KMF under the FLS1 effect; 6, KMF and UDPG are synthesized into astragalin under the UGT78K2 effect. According to the method, few steps are adopted, the operation condition is mild, few side products are generated, the yield is large, pollution is avoided, and the production cost is remarkably reduced.
Owner:YANGZHOU UNIV
Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
The present invention provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having or at risk of having diabetic cardiomyopathy a therapeutically effective amount of a glycogen phosphorylase inhibitor. The present invention also provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having 1) diabetes and 2) having cardiovascular disease, ischemic heart disease, congestive heart failure, congestive heart failure but not having coronary arteriosclerosis, hypertension, diastolic blood pressure abnormalities, microvascular diabetic complications, abnormal left ventricular function, myocardial fibrosis, abnormal cardiac function, pulmonary congestion, small vessel disease, small vessel disease without atherosclerotic cardiovascular disease or luminal narrowing, coagulopathy, cardiac contusion, or having had or at risk of having a myocardial infarction a therapeutically effective amount of a glycogen phosphorylase inhibitor.
Owner:PFIZER INC
Photoaffinity labeling marker probe molecule for marking serum glycogen phosphorylase concentration level as well as preparation method and medical application of photoaffinity labeling marker probe molecule
The invention relates to the field of medicinal chemistry, in particular to a photoaffinity labeling marker probe molecule as well as a preparation method and medical application thereof. The probe molecule can be used for selectively marking glycogen phosphorylase in serum, and then the glycogen phosphorylase can be qualitatively and quantitatively detected, so that the probe molecule can be applied to marking detection on a biochemistry marker, namely, glycogen phosphorylase when diseases such as myocardial infarction, angina, arrhythmia, ischemic sudden cardiac arrest and coronary heart disease occur.
Owner:CHENGDE MEDICAL UNIV
Lactam glycogen phosphorylase inhibitors and method of use
A compound of formula IwhereinW is a bicyclic hetroaryl of the structureX is —O—, —S—, —SO2—, —CHR5—, —CHR5O—, —CHR5S—, —CHR5SO2—, —CHR5CO— or —CH2CHR5—;Y is a bond or —CHR6—;Z is an aryl or heteroaryl group of the following structure:A is —CH— or —N—;B is —O— or —S—; andR1, R2, R3, R4, R5, R6, R7 and R8 are as described herein.Further provided is a method for treating diabetes and related diseases employing a glycogen phosphorylase inhibiting amount of the above compound, either alone or in combination with another therapeutic agent.
Owner:BRISTOL MYERS SQUIBB CO
Lactam glycogen phosphorylase inhibitors and method of use
A compound of formula I wherein W is a bicyclic hetroaryl of the structure X is —O—, —S—, —SO2—, —CHR5—, —CHR5O—, —CHR5S—, —CHR5SO2—, —CHR5CO— or —CH2CHR5—; Y is a bond or —CHR6—; Z is an aryl or heteroaryl group of the following structure: A is —CH— or —N—; B is —O— or —S—; and R1, R2, R3, R4, R5, R6, R7 and R8 are as described herein. Further provided is a method for treating diabetes and related diseases employing a glycogen phosphorylase inhibiting amount of the above compound, either alone or in combination with another therapeutic agent.
Owner:BRISTOL MYERS SQUIBB CO
Molecular markers of early liver cancer and application of makers
InactiveCN102175864AHigh detection sensitivityImprove featuresMaterial analysisTrue positive rateLiver cancer
The invention provides molecular markers of early liver cancer and application of the markers. The molecular markers of early liver cancer comprise amino-acylase-1 (ACY1), sulphite oxidase (SUOX) and glycogen phosphorylase (PYGL). The invention further provides an application of ACY1, SUOX and PYGL as molecular markers of early liver cancer in preparation of liver cancer clinical diagnostic reagents. The invention further provides a liver cancer diagnostic kit, wherein the liver cancer diagnostic kit is characterized by comprising ACY1 antibody, SUOX antibody and PYGL antibody. In the invention, new molecular markers of early liver cancer are discovered and have relatively high detection sensitivity and specificity.
Owner:JIANGSU ETERN
Azo bond contained glycogen phosphorylase inhibitor cholic acid derivative and preparation method and medical application thereof
The invention relates to an azo bond contained glycogen phosphorylase inhibitor cholic acid derivative, a preparation method thereof and a pharmaceutical composition containing the same. The azo bond contained glycogen phosphorylase inhibitor cholic acid derivative is a liver-targeted pro-drug for glycogen phosphorylase; compared with a glycogen phosphorylase inhibitor, the concentration of the glycogen phosphorylase inhibitor in a liver can be increased after the glycogen phosphorylase inhibitor cholic acid derivative is taken orally, so that the glycogen phosphorylase inhibitor cholic acid derivative can serve as a preferred drug for lowering blood sugar, particularly for treating impaired fasting glucose. The compound can be used for preventing and treating diabetes and complications thereof, hyperlipidemia, obesity, high-glucagon disease, insulin resistance, impaired fasting glucose, hypertension and complications thereof, atherosclerosis, metabolic syndrome or tumor.
Owner:CHENGDE MEDICAL UNIV
Indole-2-Carboxylic Acid Hydrazides
Compounds of formula (I) or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia, e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth.
Owner:PROSIDION LIMITED
Glycogen phosphorylase inhibitor cholic acid derivative containing bio-cleavable dipeptide and preparation method and medical application thereof
The invention relates to a glycogen phosphorylase inhibitor cholic acid derivative containing bio-cleavable dipeptide, a preparation method thereof and a pharmaceutical composition containing the same. The glycogen phosphorylase inhibitor cholic acid derivative is a liver-targeted pro-drug for glycogen phosphorylase; compared with a glycogen phosphorylase inhibitor, the concentration of the glycogen phosphorylase inhibitor in a liver can be increased after the glycogen phosphorylase inhibitor cholic acid derivative is taken orally, so that the glycogen phosphorylase inhibitor cholic acid derivative can serve as a preferred drug for lowering blood sugar, particularly for treating impaired fasting glucose. The compound can be used for preventing and treating diabetes and complications thereof, hyperlipidemia, obesity, high-glucagon disease, insulin resistance, impaired fasting glucose, hypertension and complications thereof, atherosclerosis, metabolic syndrome or tumor.
Owner:CHENGDE MEDICAL UNIV
Agricultural seed treatment agent and preparation method thereof
InactiveCN105165903AActivation of disease resistance gene expressionProphylactic treatmentBiocidePlant growth regulatorsPurslane extractSeed treatment
The invention relates to an agricultural seed treatment agent. The agricultural seed treatment agent consists of the following components in parts by mass: 56 to 60 parts of sodium lignin sulfonate, 58 to 62 parts of borax, 54 to 58 parts of prochloraz, 58 to 62 parts of clothianidin, 54 to 58 parts of chlorothalonil, 58 to 62 parts of antibacterial peptide, 54 to 58 parts of phoxim, 60 to 64 parts of sodium tungstate, 54 to 58 parts of thifluzamide, 58 to 62 parts of indoleacetic acid, 54 to 58 parts of starch dextrin, 58 to 62 parts of glyphosate, 54 to 58 parts of diniconazole, 58 to 62 parts of (hydroxyethylidene) diphosphonic acid, 54 to 58 parts of dimethomorph, 58 to 62 parts of calcium chloride, 54 to 58 parts of purslane extract solution, 58 to 62 parts of polyoxyethylene, 54 to 58 parts of lauryl sodium sulfate, 58 to 62 parts of zinc methyl arsenate, 54 to 58 parts of carbosulfan and 58 to 62 parts of glycogen phosphorylase. The preparation method of the agricultural seed treatment agent is simple, the prepared product has better antibacterial and mold-proof performance, the agricultural seed germination rate is greatly improved and the agricultural seed treatment agent is suitable for use in the agricultural field.
Owner:HEZHOU UNIV
Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
InactiveUS20050054618A1Easy to useIncrease successBiocidePeptide/protein ingredientsHeart transplantationCoronary artery disease
The present invention provides methods of treatment and prevention of early cardiac and early cardiovascular diseases, for instance of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.
Owner:RYTVED KLAUS ASGER +4
Pharmaceutical composition of glycogen phosphorylase inhibitors
InactiveCN1418089AIncrease concentrationImprove bioavailabilityAntibacterial agentsPowder deliveryGlycogen phosphorylasePolymer
The present invention relates to harmaceutical compositions that comprise a glycogen phosphorylase inhibitor and at least one concentration-enhancing polymer. The composition may be a simple physical mixture of glycogen phosphorylase inhibitor and concentration-enhancing polymer or a dispersion of glycogen phosphorylase inhibitor and polymer.
Owner:PFIZER PRODS ETAT DE CONNECTICUT
Glycogen phosphorylase inhibitor bile acid derivatives containing azo bond, preparation method and medical application thereof
Owner:CHENGDE MEDICAL UNIV
Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
Owner:PROSIDION LIMITED
(3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
The invention features pharmaceutically active quinoxalinones of formula (1), compositions containing them, and methods of making and using theme: Formula (I) wherein R<1> is H, C 1-6 alkyl, or halo; R<2> is H or halo; R<3> is H, C 1-6 alkyl, X is N or CH; Y is a covalent bond, -NHCO- or -CONH-; Z is phenyl or a 5 or 6-membered heterocyclyl with between l and 2 heteroatoms independently selected from N, O, and S; and n is 0, 1 or 2; or a pharmaceutically acceptable salt, ester, amide, hydrate, or solvate thereof; as well as their use as glycogen phosphorylase inhibitors for the treatment of i diabetes and obesity.
Owner:JANSSEN PHARMA NV
Glycogen phosphorylase inhibitor and preparation method and application thereof
InactiveCN106046101AHas inhibitory effectOrganic active ingredientsMetabolism disorderDecompositionDrugs synthesis
The invention belongs to the technical field of drug synthesis and discloses a glycogen phosphorylase inhibitor and a preparation method and application thereof. The gGlycogen phosphorylase inhibitor has a structural general formula shown as a formula (1) or pharmaceutically-acceptable salt or ester, wherein each of X1, X2, X3 and X4 is a carbon atom connecting group, or one of X1, X2, X3 and X4 is a nitrogen atom connecting group while each of the others is a carbon atom connecting group; R is H, halogen, hydroxyl, cyan, alkyl of C1-6, alkoxy of C1-6, trifluromethyl, vinyl or acetylenyl. The glycogen phosphorylase inhibitor of a novel structure has inhibiting effect on glycogen phosphorylase, is equivalent to PSN-357 in glycogenolysis inhibiting effect on a cell level and can be used for preparing drugs for treating diabetes and complications thereof, hyperlipemia, hypertension and complications thereof, atherosis, obesity and metabolic syndrome.
Owner:SOUTH CHINA UNIV OF TECH
Germination accelerating processing agent having antibiosis function for Brazilian cherry seeds
InactiveCN104488967ADoes not affect activityQuality assuranceBiocidePlant growth regulatorsAntibiosisSulfate zinc
The invention discloses a germination accelerating processing agent having antibiosis function for Brazilian cherry seeds, which comprises the following components by weight: 100 parts of ethanol, 28-35 parts of isovitamin C sodium salt, 13-17 parts of glycogen phosphorylase, 2-6 parts of citric acid and 0.2-1 part of zinc sulfate. According to the tissue structure, the germination accelerating processing agent having antibiosis function for Brazilian cherry seeds enables cell wall tissue dissociation with pertinency, cell wall of the Brazilian cherry seeds can be softened for disintegration, activity of seeds can not be influenced, shooting rate can reach more than 95%, intrusion of bacteria can be effectively avoided, and seed quality can be ensured.
Owner:LIUZHOU TIANZI HORTICULTURE
Use of pentacyclic triterpene compound as glycogen phosphorylase inhibitor
An application of the pentacyclo-triterpenoid used as the glycogen phosphorylase for preparing the medicines to treat diabetes, ischemic cardiovascular and cerebrovascular diseases, and tumor is disclosed.
Owner:CHINA PHARM UNIV
Near infrared fluorescence detection kit for glycogen phosphorylase isoenzyme BB
ActiveCN104897631AEasy to collectSimple processing capacityFluorescence/phosphorescenceReagent stripGlass fiber
The invention discloses a near infrared fluorescence detection kit for glycogen phosphorylase isoenzyme BB and application of the near infrared fluorescence detection kit. The near infrared fluorescence detection kit comprises a reagent strip on a backboard, wherein the reagent strip comprises a sample pad, a glass fiber film marked by an immunofluorescence probe, a nitrocellulose membrane coated by the anti-glycogen phosphorylase isoenzyme BB antibody, and absorbent paper. According to the invention, by combining with the near infrared fluorescence detection technology, the detection kit can rapidly and accurately detect the glycogen phosphorylase isoenzyme BB in human whole blood, serum and plasma.
Owner:SHANGHAI CHEMTRON BIOTECH
A pretreatment agent for wolfberry seed wall breaking
InactiveCN103690678BPrevent intrusionImprove broken rateMagnoliophyta medical ingredientsPlant ingredientsBiotechnologyLycium barbarum fruit
Owner:GUANGXI UNIVERSITY OF TECHNOLOGY
Compound as well as preparation method and application thereof
ActiveCN104693264AGP inhibitory activity is goodKeep aliveOrganic active ingredientsMetabolism disorderCholic acidBlood sugar
The invention discloses a compound having a structure formula I as shown in the specification, a preparation method and application thereof as well as pharmaceutically acceptable salts or esters of the compound. The compound is a novel cholic acid conjugated pyrrole amide based glycogen phosphorylase inhibitor, can take effect on glycogen phosphorylase of the liver effectively and can function as an optimal medicine for patients with type II diabetes to control blood sugar. The compound can be used for preparing medicines for resisting diabetes and complication thereof, medicines for resisting cardiovascular diseases, medicine for reducing weight and medicines for treating metabolic syndromes.
Owner:SOUTH CHINA UNIV OF TECH
Glycogen phosphorylase inhibitor bile acid derivatives containing biocleavable dipeptide, its preparation method and medical application
The invention relates to a kind of glycogen phosphorylase inhibitor cholic acid derivatives containing biocleavable dipeptides, their preparation method and their drug combination. The derivatives are liver-targeting prodrugs of glycogen phosphorylase, and the biocleavable dipeptide can be cleaved by enzymes in vivo to release glycogen phosphorylase inhibitors. Such compounds can be used to prevent and treat diabetes and its complications, hyperlipidemia, obesity, hyperglucagonism, insulin resistance, fasting hyperglycemia, hypertension and its complications, atherosclerosis, metabolic Syndrome or tumor.
Owner:CHENGDE MEDICAL UNIV
Medlar seed tissue decomposition agent
InactiveCN103735731AQuick releaseCompletely disintegratedFood preparationPlant ingredientsSulfate zincCholinesterase
The invention discloses a medlar seed tissue decomposition agent which comprises the following components by weight: 100 parts of ethanol, 10-15 parts of triethylamine, 2-5 parts of cholinesterase, 2-5 parts of glycogen phosphorylase, 0.5-1 part of calcium chloride, and 0.02-0.6 part of zinc sulfate. The medlar seed tissue decomposition agent provided in the invention performs specific cell wall tissue dissociation according to the structure and tissue of medlar seed cell walls, realizes thorough decomposition of medlar seed cell walls under a common mechanical wall breaking condition, and thus realizes complete and rapid release of effective components in cells.
Owner:GUANGXI UNIVERSITY OF TECHNOLOGY
Glycogen phosphorylase isoenzyme bb near-infrared fluorescence detection kit
ActiveCN104897631BEasy to collectSimple processing capacityFluorescence/phosphorescenceReagent stripAntiendomysial antibodies
The invention discloses a near infrared fluorescence detection kit for glycogen phosphorylase isoenzyme BB and application of the near infrared fluorescence detection kit. The near infrared fluorescence detection kit comprises a reagent strip on a backboard, wherein the reagent strip comprises a sample pad, a glass fiber film marked by an immunofluorescence probe, a nitrocellulose membrane coated by the anti-glycogen phosphorylase isoenzyme BB antibody, and absorbent paper. According to the invention, by combining with the near infrared fluorescence detection technology, the detection kit can rapidly and accurately detect the glycogen phosphorylase isoenzyme BB in human whole blood, serum and plasma.
Owner:SHANGHAI CHEMTRON BIOTECH
Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.
Owner:PROSIDION LIMITED
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com